INAB
Price:
$0.2396
Market Cap:
$17.37M
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incy...[Read more]
Industry
Biotechnology
IPO Date
2021-07-30
Stock Exchange
NASDAQ
Ticker
INAB
According to IN8bio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 18.84M. This represents a change of -38.30% compared to the average of 30.53M of the last 4 quarters.
The mean historical Enterprise Value of IN8bio, Inc. over the last ten years is 89.03M. The current 18.84M Enterprise Value has changed 2.02% with respect to the historical average. Over the past ten years (40 quarters), INAB's Enterprise Value was at its highest in in the June 2021 quarter at 177.50M. The Enterprise Value was at its lowest in in the March 2018 quarter at 0.
Average
89.03M
Median
52.29M
Minimum
24.82M
Maximum
192.94M
Discovering the peaks and valleys of IN8bio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 240.05%
Maximum Annual Enterprise Value = 192.94M
Minimum Annual Increase = -72.78%
Minimum Annual Enterprise Value = 24.82M
Year | Enterprise Value | Change |
---|---|---|
2023 | 24.82M | -31.29% |
2022 | 36.13M | -24.48% |
2021 | 47.84M | -72.78% |
2020 | 175.73M | -8.92% |
2019 | 192.94M | 240.05% |
The current Enterprise Value of IN8bio, Inc. (INAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
36.26M
5-year avg
95.49M
10-year avg
89.03M
IN8bio, Inc.’s Enterprise Value is less than Reviva Pharmaceuticals Holdings, Inc. (64.86M), less than Cue Biopharma, Inc. (40.13M), less than Lantern Pharma Inc. (26.54M), less than Gracell Biotechnologies Inc. (5.66B), less than Anixa Biosciences, Inc. (82.05M), less than INmune Bio, Inc. (68.25M), less than PolyPid Ltd. (30.18M), greater than Zura Bio Limited (-26945981.00), less than Annexon, Inc. (505.42M), less than Icosavax, Inc. (713.87M), less than Wave Life Sciences Ltd. (1.75B), less than Gain Therapeutics, Inc. (31.43M), greater than TFF Pharmaceuticals, Inc. (-2265301.00), less than aTyr Pharma, Inc. (138.44M), greater than Palisade Bio, Inc. (-2759556.00), greater than ContraFect Corporation (-2858930.00), greater than Allarity Therapeutics, Inc. (-12426398.00), greater than CNS Pharmaceuticals, Inc. (-647143.00), greater than Windtree Therapeutics, Inc. (2.60M),
Company | Enterprise Value | Market cap |
---|---|---|
64.86M | $70.33M | |
40.13M | $63.03M | |
26.54M | $34.35M | |
5.66B | $989.87M | |
82.05M | $83.04M | |
68.25M | $98.89M | |
30.18M | $24.97M | |
-26945981.00 | $161.28M | |
505.42M | $555.35M | |
713.87M | $769.04M | |
1.75B | $2.03B | |
31.43M | $42.71M | |
-2265301.00 | $288.80K | |
138.44M | $131.12M | |
-2759556.00 | $4.92M | |
-2858930.00 | $0 | |
-12426398.00 | $4.70M | |
-647143.00 | $6.29M | |
2.60M | $2.89M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IN8bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like IN8bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is IN8bio, Inc.'s Enterprise Value?
What is the highest Enterprise Value for IN8bio, Inc. (INAB)?
What is the 3-year average Enterprise Value for IN8bio, Inc. (INAB)?
What is the 5-year average Enterprise Value for IN8bio, Inc. (INAB)?
How does the current Enterprise Value for IN8bio, Inc. (INAB) compare to its historical average?